Medical - Care Facilities
Compare Stocks
2 / 10Stock Comparison
NHC vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
NHC vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology |
| Market Cap | $2.63B | $1721.78T |
| Revenue (TTM) | $1.50B | $0.00 |
| Net Income (TTM) | $101M | $-168M |
| Gross Margin | 38.5% | — |
| Operating Margin | 8.1% | — |
| Forward P/E | 21.3x | — |
| Total Debt | $87M | $22M |
| Cash & Equiv. | — | $194M |
NHC vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| National HealthCare… (NHC) | 100 | 252.6 | +152.6% |
| DBV Technologies S.… (DBVT) | 100 | 41.4 | -58.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NHC vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NHC carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 12 yrs, beta 0.60, yield 1.5%
- Rev growth 13.2%, EPS growth 17.5%, 3Y rev CAGR 11.0%
- 195.8% 10Y total return vs DBVT's -86.8%
DBVT is the clearest fit if your priority is momentum.
- +114.1% vs NHC's +80.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 13.2% revenue growth vs DBVT's -100.0% | |
| Quality / Margins | 6.7% margin vs DBVT's 0.3% | |
| Stability / Safety | Beta 0.60 vs DBVT's 1.26, lower leverage | |
| Dividends | 1.5% yield; 12-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +114.1% vs NHC's +80.9% | |
| Efficiency (ROA) | 6.4% ROA vs DBVT's -89.0% |
NHC vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
NHC vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NHC and DBVT operate at a comparable scale, with $1.5B and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.5B | $0 |
| EBITDAEarnings before interest/tax | $166M | -$112M |
| Net IncomeAfter-tax profit | $101M | -$168M |
| Free Cash FlowCash after capex | $147M | -$151M |
| Gross MarginGross profit ÷ Revenue | +38.5% | — |
| Operating MarginEBIT ÷ Revenue | +8.1% | — |
| Net MarginNet income ÷ Revenue | +6.7% | — |
| FCF MarginFCF ÷ Revenue | +9.8% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +12.5% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -8.4% | +91.5% |
Valuation Metrics
DBVT leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $2.6B | $1721.78T |
| Enterprise ValueMkt cap + debt − cash | $2.7B | $1721.78T |
| Trailing P/EPrice ÷ TTM EPS | 22.09x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 21.26x | — |
| PEG RatioP/E ÷ EPS growth rate | 0.96x | — |
| EV / EBITDAEnterprise value multiple | 15.67x | — |
| Price / SalesMarket cap ÷ Revenue | 1.79x | — |
| Price / BookPrice ÷ Book value/share | 2.47x | 0.66x |
| Price / FCFMarket cap ÷ FCF | 17.68x | — |
Profitability & Efficiency
NHC leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
NHC delivers a 9.6% return on equity — every $100 of shareholder capital generates $10 in annual profit, vs $-130 for DBVT. NHC carries lower financial leverage with a 0.08x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs NHC's 2/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +9.6% | -130.2% |
| ROA (TTM)Return on assets | +6.4% | -89.0% |
| ROICReturn on invested capital | +8.4% | — |
| ROCEReturn on capital employed | — | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.08x | 0.13x |
| Net DebtTotal debt minus cash | $87M | -$172M |
| Cash & Equiv.Liquid assets | — | $194M |
| Total DebtShort + long-term debt | $87M | $22M |
| Interest CoverageEBIT ÷ Interest expense | 24.41x | -189.82x |
Total Returns (Dividends Reinvested)
NHC leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NHC five years ago would be worth $25,292 today (with dividends reinvested), compared to $3,344 for DBVT. Over the past 12 months, DBVT leads with a +114.1% total return vs NHC's +80.9%. The 3-year compound annual growth rate (CAGR) favors NHC at 46.0% vs DBVT's 6.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +30.4% | +5.5% |
| 1-Year ReturnPast 12 months | +80.9% | +114.1% |
| 3-Year ReturnCumulative with dividends | +211.1% | +20.4% |
| 5-Year ReturnCumulative with dividends | +152.9% | -66.6% |
| 10-Year ReturnCumulative with dividends | +195.8% | -86.8% |
| CAGR (3Y)Annualised 3-year return | +46.0% | +6.4% |
Risk & Volatility
NHC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NHC is the less volatile stock with a 0.60 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NHC currently trades 92.0% from its 52-week high vs DBVT's 76.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.60x | 1.26x |
| 52-Week HighHighest price in past year | $184.08 | $26.18 |
| 52-Week LowLowest price in past year | $93.54 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +92.0% | +76.8% |
| RSI (14)Momentum oscillator 0–100 | 48.4 | 43.8 |
| Avg Volume (50D)Average daily shares traded | 117K | 253K |
Analyst Outlook
NHC leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
NHC is the only dividend payer here at 1.46% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $46.33 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | +1.5% | — |
| Dividend StreakConsecutive years of raises | 12 | 0 |
| Dividend / ShareAnnual DPS | $2.47 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | 0.0% |
NHC leads in 4 of 6 categories (Profitability & Efficiency, Total Returns). DBVT leads in 2 (Income & Cash Flow, Valuation Metrics).
NHC vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is NHC or DBVT a better buy right now?
National HealthCare Corporation (NHC) offers the better valuation at 22.
1x trailing P/E (21. 3x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — NHC or DBVT?
Over the past 5 years, National HealthCare Corporation (NHC) delivered a total return of +152.
9%, compared to -66. 6% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: NHC returned +195. 8% versus DBVT's -86. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — NHC or DBVT?
By beta (market sensitivity over 5 years), National HealthCare Corporation (NHC) is the lower-risk stock at 0.
60β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 111% more volatile than NHC relative to the S&P 500. On balance sheet safety, National HealthCare Corporation (NHC) carries a lower debt/equity ratio of 8% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — NHC or DBVT?
On earnings-per-share growth, the picture is similar: National HealthCare Corporation grew EPS 17.
5% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — NHC or DBVT?
National HealthCare Corporation (NHC) is the more profitable company, earning 8.
2% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 8. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NHC leads at 8. 7% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — NHC leads at 37. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — NHC or DBVT?
In this comparison, NHC (1.
5% yield) pays a dividend. DBVT does not pay a meaningful dividend and should not be held primarily for income.
07Is NHC or DBVT better for a retirement portfolio?
For long-horizon retirement investors, National HealthCare Corporation (NHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
60), 1. 5% yield, +195. 8% 10Y return). Both have compounded well over 10 years (NHC: +195. 8%, DBVT: -86. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between NHC and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
NHC pays a dividend while DBVT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.